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ABSTRACT 
There is little published research in mainstream Indian journals of the clinical psychotropic 
properties of herbal medicines. The present study therefore evaluated the psychotropic effects of 
Memorin (from a pharmaceutical house based at Maharashtra), a herbal formulation. Subjects 
with DSM-IV age-related cognitive decline were randomized to receive Memorin (n=22) or placebo 
(n=23) for three months. Before and after treatment, all subjects completed a battery of neuropsy-
chological tests that assessed visual and verbal memory, visuospatial skills, and perceptuomotor 
functioning Subjects and rater were alike blind to treatment group. The results revealed that in the 
Memorin group, on most tests significant improvement in performances were observed after treat-
ment; improvement in many of the memory tasks was however confined to males; age did not 
significantly influence the results. In contrast, in placebo-treated subjects there was little thera-
peutic gain. It is concluded that irrespective of the subject's actual age, Memorin may benefit 
elderly persons, particularly males, who experience age-related cognitive decline. 
Key words : Age-related cognitive decline, cognition, drug trial, elderly, herbal pharmaco-
therapy, neuropsychological changes, sex differences 
India has a rich tradition in herbal medi-
cine, and a number of herbs with psychotropic 
properties have been identified; these include 
Shankapushpi, Brahmi, Ashwagandha, 
Mandookaparni and others (for review, see 
Iyengar, 1981; Dhawan, 1995; Handa, 1995; 
Satyavati, 1995). While a large number of pre-
clinical studies have identified potential psycho-
tropic applications of various herbal formula-
tions (Andrade, 1995; Andrade et al., 1994; 
1995; Joseph et al., 1994; Faruqi et al., 1995; 
Ramteke et al , 1995), few clinical studies on 
these herbs and formulations have been pub-
lished in mainstream Indian journals. In particu-
lar, not a single clinical study on the subject 
has been published in the Indian Journal of 
Psychiatry since 1985. 
Such a poverty of publications suggest a 
neglect of research into traditional strengths in 
Indian medicine. Allopathic science may 
derive much gain from herbal medical practices. 
Very many important allopathic drugs, such as 
digitalis, quinine and atropine, originated from 
plant sources; the Indian herbal pharmacopoeia 
contributed reserpine to modem medicine. 
The need to study the psychotropic prop-
erties of herbal drugs is recognised even in the 
west; for example, clinical research on St. 
John's Wort (Linde et al., 1996) has recently 
been reviewed in the British Medical Journal. 
American laboratories are already screening 
individual herbs for psychotropic potential; 
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the USA efforts in this regard have been 
summarized by Cott (1995). By way of exam-
P pie, Cott et al. (1994) reported that extracts from 
Withania somnifera (Ashwagandha) show high 
affinity for GABA receptors, and that extracts 
from Centella asiatica (Mandookaparni) show 
affinity for CCK receptors. Since GABA agonism 
and CCK antagonism have been linked to anxi-
olysis, these findings support the recommen-
dation in Ayurveda (a traditional system of 
herbal medicine in India) that Ashwagandha and 
Mandookaparni be used for tranquillization 
(Handa, 1995). Therefore the Indian psychia-
trists should take a closer look at what is 
available at their doorstep. The present study 
was designed with this objective in mind. 
Memorin (from a pharmaceutical house 
based at Maharashtra*) is a herbal formulation 
derived from Mandookaparni, Jatamansi, 
Yashtimadhu, Shankapushpi and Smruti Sagar. 
These ingredients have been suggested in Ay-
urveda to be brain tonics, anti -stress agents, 
and vitalizers (lyenger, 1981; Dhawan, 1995; 
Handa, 1995; Satyavati, 1995). Memorin is for-
mulated in accordance with principles laid down 
in Ayurveda, and the various constituents are 
suggested to complement each others, actions. 
The formulation has been commercially 
available since 1983. 
Preliminary research on Memorin, 
conducted on animal models, has demonstrated 
that Memorin attenuates anterograde and 
retrograde amnesia induced by electroconvul-
sive shocks (Vinekar et al., 1998; Andrade et 
al., 1998). The present study sought to 
ascertain whether intermediate-term therapy 
with Memorin benefits normal elderly subjects 
who experience cognitive decline. 
MATERIAL AND METHOD 
The sample comprised subjects recruited 
from three homes for the elderly located within 
the boundaries of Bangalore city. To be eligible 
for participation in the study, all subjects had to 
meet the DSM-IV description of A je-related 
cognitive decline (American Psychiatric 
*Phyto Pharma, Kolhapur are manufacturer* of Mamorin. 
Association, 1994; see appendix). The DSM 
description was operationalized as follows: the 
purpose of the study was explained to the 
residents of the homes, and volunteers for the 
study were invited; all volunteers were required 
to provide clear examples of forgetfulness or 
decreased intellectual ability in their day to day 
lives to be considered for inclusion. All 
volunteers were also required to be physically 
and mentally healthy, as certified by the 
attendant physician at the home, and as 
subsequently confirmed during the screening 
assessments. Finally, all volunteers were 
required to be non-smokers and teetotallers. 
With these selection criteria specified, 45 
volunteers were obtained. The subjects 
provided a clinical history and underwent 
physical and mental status examination to 
confirm their suitability for the study. All 45 
candidates were found suitable. Informed 
consent for participation in the study was 
obtained in writing. 
The following neuropsychological tests 
were administered at baseline : 
1. Complex passage test (Mukundanetal., 1983 
& 1991) : three trials and one delayed recall 
assessment. 
2. Complex figure test (Mukundan et al., 1983 
& 1991) : three trials and one delayed recall 
assessment. 
3. Block Design Test (Ancttade and Mukundan, 
1996): first 5 tasks. 
4. Digit Symbol Substitution Test (Andrade and 
Mukundan, 1996). 
5. Selective Reminding Test (Buschke and Fuld, 
1974). 
The complex passage and complex 
figure tests assess verbal and visual memory 
respectively. The Block Design test assesses 
visuospatial skills and perceptuomotor speed. 
The Digit Symbol Substitution Test assesses 
scanning and perceptuomotor speed. The 
Selective Reminding Test assesses different 
aspects of verbal and visual memory : short-
term storage, long-term storage, and retrieval. 
Subjects were also rated on the 
Hamiltion scales for anxiety and depression 
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(Bech et al„ 1986). Subsequently, the subjects 
were randomized to receive either Memorin or 
placebo. Treatments were administered in the 
form of identical capsules, to be taken on an 
empty stomach in the dose of two capsules 
twice a day. Neither subjects nor rater knew the 
treatment group to which the subjects 
were assigned. The study were therefore 
double-blind. 
Regular contact was maintained with the 
subjects to confirm compliance by pill counts 
and to effect troubleshooting, if required. 
Compliance was found to be excellent, and no 
distress interventions were necessary. After 
three months of treatment, the subjects were 
assessed once more on the tests and scales 
administered at baseline Adverse effects with 
treatment were evaluated using the Systematic 
Assessment for Treatment Emergent Effects 
(SAFTEE) symptom ctfecklist (Levine and 
Schooler, 1986). Subjective improvement in 
cognition was rated using the Clinical Global 
Impression scale (Guy, 1976). Finally, subjects 
were asked whether they wished to continue or 
discontinue the treatment that they were 
receiving. 
Statistical analysis : Performances on 
various tests were compared before and after 
treatment using multivariate analyses of vari-
ance (MANOVA) based on Pillai's criterion. 
There were one or two repeating measures in-
troduced, depending on the test; time (before 
vs after treatment with Memorin/placebo) was 
the invariable repeating measure, and subtest' 
(e.g. 4 trials on each testing occasion in the 
visual and the verbal memory tasks; 5 tasks on 
each testing occasion in the block design test) 
was the second repeating measure, wherever 
applicable. Sex (male vs female) was the in-
variable between subjects factor. 
Pearson's product moment correlation 
coefficients were computed to test the 
relationship between age and improvement on 
various measures on each test. Alpha for 
statistical significance was set at 0.05 for the 
MANOVAs and 0.01 for the correlations; the 
latter sought to attenuate the risk for type 1 
errors. 
Due to idiosyncratic circumstances, all 
subjects did not complete all tests; these varia- 1 
tions in sample size for individual tests are 
reflected in the degrees of freedom. 
RESULTS 
A total of 45 subjects were recruited, of 
whom 22 received Memorin and 23 received 
placebo. A comparison of baseline perform-
ances on the neuropsychological tests revealed 
TABLE 1 
M (SC) MEMORY SCORES ON COMPLEX PASSAGE 
(VERBAL) AND COMPLEX FIGURE (VISUAL) MEMORY 
TESTS AT BASELINE AND ENDPOINT IN SUBJECTS 
TREATED WITH MEMORIN (N=20)* 
Trial 
1 
Trial 
2 
Trial 
3 
Delayed 
Recall 
Complex passage 
baseline 15.3(4.6) 19.4(3.7)23.1(3.5) 16.7(3.7 
Complex passage 
Midpoint 18.5(3.5) 22.1(3.1 
Complex figure 
baseline 
Complex figure 
endpoint 
3.1(1.8) 
3.4 (1.5) 
4.6(2.5) 
4.6(2.4) 
25.4(2.9) 22.1(3.9] 
6.3(2.9) 
6.3(2.7) 
3.8(2.5) 
3.8 (2.5) 
* values represent number of units recalled; higher scores 
reflect better learning/recall. Endpoint scores were signifi-
cantly higher than baseline scores tor the complex passage 
test only. 
TABLE 2 
M (SO) BLOCK DESIGN SCORES AT BASELINE 
AND ENDPOINT IN SUBJECTS TRTEATED 
WITH MEMORIN (N~18)* 
Pattoml 
Pattern 2 
Pattem.3 
Pattern 4 
Pattern 5 
Baseline 
41.4(17.1) 
74.6(31.9) 
135.2(54.6) 
204 8(61.7) 
242 5(63.1) 
Endpoint 
54.0 (13.9)' 
74.5(20.9) 
126.0(45.1) 
261.8(45.8) 
274 8 (43.3) 
* values represent time (in eecs) taften to compWe task; lower 
•coves reflect better performance. 
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TABLE 3 
M (SD) VERBAL SELECTIVE REMINDING TEST 
SCORES AT BASELINE AND ENDPOINT IN SUBJECTS 
TREATED WITH MEMORIN (N-20) 
Short-term storage 
Half long-term storage 
Full long-term storage 
Consistent long-term 
retrieval 
Total trials* 
Total recall at last trial 
Baseline 
5.6(1.8) 
2.4(2.6) 
8.0(1.9) 
3.6 (2.8) 
6.5(1.4) 
8.1 (1.5) 
Endpoint Significance 
i 
5.2(1.5) NS 
3.3(2.2) p<0.009" 
7.1 (3.0) p<0.03" 
4.8(3.5) p<0.001" 
6.1(1.4) p<0.008" 
8 4 (1.8) P=0.09** 
'lower scores reflect better performance 
"significant improvement in males but not in females 
TABLE 4 
M (SD) VISUAL SELECTIVE REMINDING TEST SCRES 
. AT BASELINE AND ENDPOINT IN SUBJECTS 
TREATED WITH MEMORIN |N=19) 
Baseline Endpoint Significance 
Short-term storage 4.8(1.9) 4.9(1.9) P=0.08" 
Half long-term storage 2.5 (2.6) 2.1(3.0) NS 
Full long-term storage 7.6(2.4) 6.9(2.6) p=0.08** 
Consistent long-term 3.4 (2.8) 4.5 (3.8) p=0.02" 
retrievat 
Total trials* 6.4(1.7) 6.3(1.5) p<0.008' 
Total recall at last trial 8.2(1.5) 8.4(1.4) p=0.013" 
•lower scores reflect better performance 
"significant improvement in males but not in females 
that the Memorin and placebo groups were 
cognitively substantially different; therefore, 
intergroup (endpoint) statistical analyses could 
not be validly performed. Accordingly, only the 
findings with Memorin-treated subjects are high-
lighted, making this an uncontrolled bui 
double-blind study. In order that the findings 
be placed in perspective, howevt r, the results 
in the placebo-treated subjects are also 
presented, albeit in summary. 
Endpoint data were unavailable for two 
Memorin-treated subjects because they left the 
homes in which they had been staying. Of the 
remaining subjects, 8 were male and 14 were 
female. Trie age of the sample ranged from 
59-86 years, with a mean (standard deviation) 
[M (SD)] of 72.8 (7.2) years. Males and females 
did not differ significantly in age. Males and 
females also did not differ significantly in 
baseline performances on any of the tests. 
The Complex Passage and Complex 
Figure memory performances at baseline and 
endpoint in Memorin-treated subjects are 
presented in table 1. There was a significantly 
main effect for time in the complex passage 
test (F=12. 91, d.f.=1.18, p<0.002), indicating 
improved learning at the treatment endpoint. 
In the visual memory test, however, there was 
no significant change at the end of the 
treatment period. In neither task was there a 
difference in performance between males and 
females. 
The Block Design performances at 
baseline and endpoint in Memorin-treated 
subjects are presented in table 2. There was 
no significant change at the end of the treat-
ment period, nor were there differences in 
performances between males and females. 
The M (SD) time taken by Memorin-
treated subjects to complete the Digit Symbol 
Substitution Test was 136.3 (45 0) sees at base-
line, and 103.7 (25.5) sees at endpoint. The 
improvement was statistically significant 
(F=14.61, d.f.=1.16, p<0.002). Males and fe-
males did not differ in performances 
The performances of Memorin-treated 
subjects on the verbal and visual Selective 
Reminding Tests are presented in tables 3 and 
4 respectively. For the verbal test, short-term 
storage scores did not improve significantly at 
endpoint. On the remaining elements of the 
verbal test, half long-term storage (F=8.72, 
d.f =1, 18, p<0.009), full long-term storage 
(F=5 71, d.f.=1,18, p<0.03), consistent long-
term retrieval (F=15.58, d.f.=1,18, p<0.001), to-
tal number of trials (F=8.79, d.f.=1, 18, 
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p<0.008) and total recall at last trial (F=3.19, 
d.f.=1,18, p=0.091) improved significantly only 
in males. 
For the visual test, short-term storage 
(F=3 48, d f.=1,16, p=0.08), full long-term 
storage (F=3 43, d.f.=1,16, p=0.084), consist-
ent long-term retrieval (F=6.88, d.f.=1,16, 
p=0.019), and total trials (F=7.90, d.f.=1,16, 
p=0.013), showed significant or near significant 
improvement only in males. There were no sig-
nificant changes in half long-term storage and 
last trial recall scores. 
In Memorin-treated subjects, for all 
measures on all tests, improvement scores were 
obtained by calculating the difference between 
baseline and endpoint scores. Two-tailed cor-
relations were examined between age and each 
improvement score. No significant correlations 
emerged, indicating that the change between 
baseline and endpoint was independent of age. 
Mean (SD) Hamilton anxiety scores in 
Memorin-treated subjects were 4.6 (2.2) at 
baseline and 3.9 (1.4) at endpoint; Mean (SD) 
Hamilton depression scores were 5.0 (2.1) at 
baseline and 3.9 (1.6) at endpoint. There were 
no significant changes, nor did males and fe-
males differ. 
The Mean (SD) Clinical Global Impres-
sion scores in Memorin-treated subjects, rating 
subjective improvement in cognitive perform-
ance in day to day life at the end of the trial, 
was 1.6 (0.9). This indicates that the partici-
pants subjective rating of improvement was in 
the high mild to moderate range. SAFTEE as-
sessments indicated no treatment-related ad-
verse events during the course of the trial. All 
subjects opted to continue Memorin beyond the 
end of the trial. 
In order that the above findings be placed 
in perspective, a summary of the findings in 
the placebo group are presented below : there 
were 9 males and 14 females, with Mean (SD) 
age of 72 8 (7.2) years. A total of 5 subjects 
reported a total of 6 treatment emergent ad-
verse effects . dysphagia (n=2), bowel distur-
bances (n=2). fatigue and tiredness (n=1) and 
tremor (n=l). Two subjects discontinued 
treatment because of the adverse effects. The 
nonspecific nature of these adverse effects how- . 
ever suggests that the complaints may have * 
been due to non-treatment causes, such as a 
low grade intercurrent bowel or other infection. 
Post-treatment improvement in the 
placebo group was observed in the complex 
passage and the digit symbol substitution tests 
only. No separate effects for males was 
observed. While all subjects who completed 
the trial opted to continue their medication, the 
overall Mean (SD) CGI rating of benefit was 
1.3 (0.7), indicating subjective experience of 
benefit in the low mild to moderate range. 
DISCUSSION 
Herbal medicines are traditionally com-
bined and administered as formulations be-
cause it is expected that such herbs exert a 
synergistic effect in combination. Very many 
patent formulations are commercially available 
in India; regrettably, little is known about the 
clinical efficacy of such formulations because 
the Drug Controller of India does not require 
clinical trials to be performed before these 
formulations are marketed. The present trial 
therefore fulfilled a felt need : it examined the 
benefits and adverse effects associated with the 
clinical use of one such formulation. 
With the exception of the complex fig-
ure and the block design tests, improvement 
was noted at the treatment endpoint on all the 
tests administered. It is conceivable that the 
improvement was due to a placebo effect, and/ 
or to a practice effect since parallel versions of 
the tests were unavailable. Two arguments, 
however, at least partially discredit the placebo 
and practice effect hypothesis. Firstly, it is hard 
to accept that subjects with cognitive decline 
will recall the elements of a task three months 
after its administration (this is particularly rel-
evant with highly abstract tasks). Secondly, it 
is hard to understand why a practice or placebo 
effect should favour males more than females. 
These arguments are supported to a fair extent 
by the relative poverty of improvement in the 
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placebo group. 
It is therefore likely that Memorin played 
"* at least some role in improving cognitive per-
formance; this supposition is strengthened by 
the observation that coexisting mood distur-
bance was unlikely to have influenced the re-
sults because no subject at either time point 
experienced anxiety or depression of clinical 
significance, and all subjects had very low 
ratings of anxiety and depression. 
Memorin benefited males more than 
females. This was a moderately consistent find-
ing. The finding is hard to explain unless one 
hypothesizes that age-related cognitive decline 
is pathogenetically heterogenous between the 
sexes. Such a hypothesis is unconfirmed but 
conceivable, because it is known that, for ex-
ample, Alzheimer's disease is commoner in 
females. This may mean that females are more 
likely to have neuropathological changes in their 
brains which do not respond well to treatments, 
herbal or otherwise. However, the subjects' 
actual age did not influence outcome, even 
though older subjects are also more likely to 
show neuropathological changes. 
Cognitive performance is well known to 
decrease with increasing age. Most elderly per-
sons complain of a mild degree of memory im-
pairment and subjective word or name finding 
disability. The prevalence of age-associated 
memory impairment, a more rigorously defined 
and restrictive diagnosis than the DSM-IV age-
related cognitive decline, is 18.5% in persons 
above the age of 50 years (Barker et a!., 1995). 
There is therefore a large population of persons 
who might benefit from the use of risk-free 
medication that improves cognitive perform-
ance. 
In conclusion : Memorin significantly 
improved cognitive performance in healthy 
I subjects with age-related cognitive decline. 
Males benefited from treatment more than did 
females. There were no treatment-related 
adverse events. All subjects chose to continue 
with their treatment at the end of the treatment 
period. In contrast, placebo-treated patients 
showed little therapeutic gain. It is therefore 
concluded that Memorin may be a useful 
treatment for the improvement of cognitive 
performance in the elderly; the formnulation 
hence merits further evaluation with a larger 
sample, in a controlled study. Such future stud-
ies should examine dose ranging effects to iden-
tify the ideal dose as well as to ascertain whether 
higher doses in women (than administered in 
this study) purvey clearer cognitive benefits. 
APPENDIX 
DSM-IV provides a description but does 
not specify diagnostic criteria for the category 
age-related cognitive.decline. According to the 
description, the focus of clinical attention should 
be an objectively identified decline in cognitive 
functioning, consequent to the ageing process, 
that is within normal limits given the subject's 
age. Example of problems that the subjects 
may complain of are forgetfulness for names 
or appointments, or difficulties in solving 
complex problems. Age-related cognitive 
delcine should be diagnosed only if the 
cognitive impairment is not attributable to a 
specific neurological or psychiatric disorder. 
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